| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
WSP-5 does not target a specific protein or enzyme; instead, it selectively reacts with hydrogen sulfide (H₂S) through a nucleophilic substitution–cyclization mechanism.
|
|---|---|
| ln Vitro |
WSP-5 exhibits a fluorescence turn-on response upon reaction with H₂S, with excitation and emission maxima at 502 nm and 525 nm, respectively. The probe shows high selectivity for H₂S over other biological thiols and reactive oxygen/nitrogen species.
|
| ln Vivo |
No significant in vivo activity data has been reported for WSP-5, as it is primarily utilized as a chemical tool for H₂S detection in biological samples rather than as a therapeutic agent.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay is not applicable as WSP-5 is a reactive chemical probe. The compound is typically dissolved in DMSO to prepare stock solutions. For H₂S detection, the probe is incubated with test samples in aqueous buffer at physiological pH (typically pH 7.4). The reaction between WSP-5 and H₂S proceeds through a disulfide exchange mechanism, and fluorescence intensity is measured at λex/λem = 502/525 nm to quantify H₂S levels.
|
| Cell Assay |
For in vitro cellular experiments, cells are incubated with WSP-5 at optimized concentrations (typically in the low micromolar range) in culture medium. After a defined incubation period, cells are washed to remove excess probe, and fluorescence intensity is measured using flow cytometry or fluorescence microscopy. The turn-on fluorescence signal correlates with intracellular H₂S levels, allowing real-time imaging and quantification of H₂S in live cells. The probe is cell-permeable, enabling efficient entry into live cells for intracellular H₂S detection.
|
| Animal Protocol |
In vivo animal model experiments have not been extensively reported for WSP-5, as it is primarily developed as an in vitro and cellular imaging probe for H₂S detection rather than an in vivo therapeutic or diagnostic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of WSP-5 have not been characterized, as the compound is a research-use fluorescent probe rather than a drug candidate. Its cell-permeable nature allows it to enter live cells for intracellular H₂S detection.
|
| Toxicity/Toxicokinetics |
The probe has a CAS number of 1593024-78-2 and a molecular weight of approximately 454.56 g/mol. Toxicological data for WSP-5 has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed when handling this chemical probe.
|
| Additional Infomation |
WSP-5 (Washington State Probe-5) belongs to the 2-pyridyl disulfide probe family developed for H₂S bioimaging applications. It is a cell-permeable fluoresceinyl pyridine disulfide compound that enables the study of H₂S-associated signaling networks in biological systems. H₂S is an important gasotransmitter that, like nitric oxide, has significant effects on the mammalian immune, nervous, cardiovascular, and pulmonary systems. The probe has not entered clinical trials or received regulatory approval for any therapeutic indication.
|
| Molecular Formula |
C44H26N2O7S4
|
|---|---|
| Molecular Weight |
822.95
|
| Exact Mass |
822.062
|
| CAS # |
1593024-78-2
|
| PubChem CID |
125181269
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.804
|
| LogP |
9.74
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
57
|
| Complexity |
1330
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)OC(=O)C5=CC=CC=C5SSC6=CC=CC=N6)OC7=C3C=CC(=C7)OC(=O)C8=CC=CC=C8SSC9=CC=CC=N9
|
| InChi Key |
DSMMZTASSIAQPQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C44H26N2O7S4/c47-41(30-12-2-5-15-37(30)54-56-39-17-7-9-23-45-39)50-27-19-21-33-35(25-27)52-36-26-28(20-22-34(36)44(33)32-14-4-1-11-29(32)43(49)53-44)51-42(48)31-13-3-6-16-38(31)55-57-40-18-8-10-24-46-40/h1-26H
|
| Chemical Name |
[3-oxo-6'-[2-(pyridin-2-yldisulfanyl)benzoyl]oxyspiro[2-benzofuran-1,9'-xanthene]-3'-yl] 2-(pyridin-2-yldisulfanyl)benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2151 mL | 6.0757 mL | 12.1514 mL | |
| 5 mM | 0.2430 mL | 1.2151 mL | 2.4303 mL | |
| 10 mM | 0.1215 mL | 0.6076 mL | 1.2151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
